Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s R ...

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...

In this week's InnovationRx newsletter, federal judges halt Trump's cuts to NIH research payments, rural hospitals' ongoing ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...

These are the most popular stories from the Financial Times. These stories have not been verified and we cannot vouch their accuracy.

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

Financial Times highlights include BP's reduced bonus payout, Entain's CEO stepping down, Novartis' acquisition of Anthos Therapeutics, and EU's planned retaliation against US tariffs on steel and ...

Health-care companies fell after disappointing earnings from one health insurer. Shares of Humana slid after the health-insurance firm warned of falling Medicare Advantage membership, and hinted that ...

Nevada reports its first human case of bird flu in a dairy worker as the outbreak expands in the U.S. The H5N1 virus has ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.